ImmunoCellular Therapeutics announced that the first patient has been enrolled in its Phase 2 trial of ICT-107 for the treatment of glioblastoma multiforme (GBM). The double-blind, placebo-controlled, 2:1 randomized study is designed to evaluate the safety and efficacy of ICT-107 in patients with newly diagnosed GBM. The study will enroll approximately 100 patients and will be conducted at an estimated 15 clinical trial centers in the U.S.
ICT-107 is the company’s dendritic cell based cancer vaccine candidate targeting multiple tumor associated antigens for glioblastoma.
For more information call (818) 992-2907 or visit www.imuc.com.